Shunned by investors, Henlius hangs up on its Hong Kong listing
The Fosun-backed drugmaker’s privatization comes as its stock price has wilted over 60% since its IPO five years ago and it failed to use the listing to raise additional funds…
Recent Articles
RELATED ARTICLES
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK -
Fosun moves on from debt crisis with renewed focus on tourism, healthcare
0656.HK
-
Fosun Tourism travels back to home base with delisting plan
1992.HK 0656.HK
-
Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
688062.SHG
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- Huge Dental hopes Hong Kong smiles on its latest listing attempt
-
Goldlion joins stock retreat as brand loses its luster
0533.HK
